Calliditas Therapeutics AB (publ) (CALT)

NASDAQ: CALT · IEX Real-Time Price · USD
18.58
+0.31 (1.71%)
At close: Sep 27, 2023, 4:00 PM
18.02
-0.56 (-3.01%)
Pre-market: Sep 28, 2023, 7:39 AM EDT
1.71%
Market Cap 498.61M
Revenue (ttm) 105.88M
Net Income (ttm) -26.91M
Shares Out 26.84M
EPS (ttm) -0.98
PE Ratio n/a
Forward PE 8.77
Dividend n/a
Ex-Dividend Date n/a
Volume 14,761
Open 18.68
Previous Close 18.27
Day's Range 17.70 - 19.00
52-Week Range 10.82 - 25.64
Beta 1.34
Analysts Strong Buy
Price Target 49.00 (+163.72%)
Earnings Date Nov 13, 2023

About CALT

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 5, 2020
Employees 169
Stock Exchange NASDAQ
Ticker Symbol CALT
Full Company Profile

Financial Performance

In 2022, CALT's revenue was 802.88 million, an increase of 250.07% compared to the previous year's 229.35 million. Losses were -412.27 million, -17.59% less than in 2021.

Financial numbers in SEK Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CALT stock is "Strong Buy." The 12-month stock price forecast is $49.0, which is an increase of 163.72% from the latest price.

Price Target
$49.0
(163.72% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Calliditas Therapeutics to Present Nefecon Data at the 17th International Symposium on IgA Nephropathy (IIgANN) September 25-27 in Tokyo

STOCKHOLM , Sept. 19, 2023 /PRNewswire/ --  Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), today announced upcoming data presentations from the NeflgArd Phase 3 Stu...

8 days ago - PRNewsWire

FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy

STOCKHOLM , Aug. 18, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT), (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the U.S. Food and Drug Administration (FDA) has acce...

5 weeks ago - PRNewsWire

Interim Report Q2, 2023: Calliditas Therapeutics

Filing for full approval of TARPEYO STOCKHOLM , Aug. 17, 2023 /PRNewswire/ -- FINANCIAL SUMMARY FOR THE GROUP Key Figures April 1 - June 30, 2023 Net sales amounted to SEK 269.4 million, of which TARP...

6 weeks ago - PRNewsWire

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

STOCKHOLM , Aug. 15, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced publication in The Lancet  of the full data from the Phase ...

6 weeks ago - PRNewsWire

Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

STOCKHOLM , July 13, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced interim data from the proof-of-concept Phase 2 trial in pat...

2 months ago - PRNewsWire

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®

STOCKHOLM , June 21, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced the submission of a supplemental New Drug Application ("sND...

3 months ago - PRNewsWire

Everest Medicines' Partner Calliditas Therapeutics Makes Data Presentations on Nefecon at European Renal Association - European Dialysis and Transplant Association Congress (ERA-EDTA )

SHANGHAI , June 20, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that its partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALT...

3 months ago - PRNewsWire

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

STOCKHOLM , May 30, 2023 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on 30 May 2023, in Stockholm. Adop...

4 months ago - PRNewsWire

Calliditas Therapeutics: Interim Report Q1, 2023

STOCKHOLM , May 16, 2023 /PRNewswire/ --  Strong eGFR Data from Positive NefIgArd Phase 3 Trial Readout "In March we announced that the global NefIgArd Phase 3 trial successfully met its primary endpo...

4 months ago - PRNewsWire

Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023

STOCKHOLM , May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the ...

5 months ago - PRNewsWire

Notice of annual general meeting of Calliditas Therapeutics AB (publ)

STOCKHOLM, April 28, 2023 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to ...

5 months ago - PRNewsWire

Calliditas Therapeutics' 2022 Annual Report Published

STOCKHOLM , April 26, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2022 now is available at the company's website:...

5 months ago - PRNewsWire

Calliditas Announces Publication of Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with IgA Nephropathy in the United States

NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marke...

6 months ago - GlobeNewsWire

Calliditas to participate in upcoming investor conferences

STOCKHOLM , March 31, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced its management's participation in the following investor co...

6 months ago - PRNewsWire

Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy

STOCKHOLM , March 13, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced positive topline results from the global, randomized, doub...

7 months ago - PRNewsWire

Calliditas - Year-End Report, 2022

2022: Successful transformation into a commercial stage company STOCKHOLM , Feb. 23, 2023 /PRNewswire/ --  "2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approv...

7 months ago - PRNewsWire

Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy

STOCKHOLM , Feb. 2, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX)  ("Calliditas") today announced that the Medicines and Healthcare products Regulatory Agenc...

8 months ago - PRNewsWire

Number of shares and votes in Calliditas Therapeutics

STOCKHOLM , Jan. 31, 2023 /PRNewswire/ -- During January, Calliditas Therapeutics AB (publ) has issued 7,500 common shares connected to the company's long term incentive program 2019/2022. Thus, as of...

8 months ago - PRNewsWire

China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy

STOCKHOLM , Dec. 30, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation (CDE) of the Chi...

9 months ago - PRNewsWire

Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2019/2022

STOCKHOLM , Dec. 21, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced today that CEO Renée Aguiar-Lucander has net purchased 50,0...

10 months ago - PRNewsWire

Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan

Calliditas announces that it has entered into an agreement with Viatris to bring Nefecon®, a specialty therapy focused on downregulating IgA1, to Japanese patients. The agreement, worth up to $100M in...

Other symbols: VTRS
10 months ago - PRNewsWire

Calliditas to host fireside chat with its China commercial partner, Everest Medicines

STOCKHOLM , Dec. 9, 2022 /PRNewswire/ --  Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a fireside chat with its commercial partner Everest Medicines (HKEX 1952.HK...

10 months ago - PRNewsWire

Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPA

STOCKHOLM , Nov. 15, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Chinese regulatory authority National Medical Prod...

11 months ago - PRNewsWire

Calliditas Therapeutics: Interim Report Q3, 2022

Conditional Marketing Authorization in EU Granted for Kinpeygo® STOCKHOLM , Nov. 14, 2022 /PRNewswire/ -- "On July 15th the European Commission issued the conditional marketing authorization for Kinpe...

11 months ago - PRNewsWire

Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape

STOCKHOLM , Nov. 7, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a Key Opinion Leader (KOL) Fireside Chat on the IgA Nephropathy (IgAN) treat...

11 months ago - PRNewsWire